Utilico Insights - Jacqueline Broers assesses why Vietnam could be the darling of Asia for investors. Watch the full video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksProvexis Regulatory News (PXS)

Share Price Information for Provexis (PXS)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 0.625
Bid: 0.60
Ask: 0.65
Change: 0.00 (0.00%)
Spread: 0.05 (8.333%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 0.625
PXS Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Pre-Close Update

30 Mar 2012 07:00

RNS Number : 4078A
Provexis PLC
30 March 2012
 



30 March 2012

Provexis plc

 

PRE-CLOSE UPDATE

 

Provexis plc ("Provexis" or the "Company"), the life-science business that develops, licenses and markets scientifically-proven functional food and sports nutrition technologies, announces a pre-close update for the year ended 31 March 2012.

 

In its preliminary results statement expected in July, the Company expects to report on a year of strong progress in which it completed and integrated the acquisition of Science in Sport ("SiS"), made good progress with its alliance partner DSM Nutritional Products ("DSM") in developing and commercialising its novel Fruitflow® heart-health technology, and underwent a major restructuring to reduce cash burn and focus on the two major commercial opportunities of SiS and Fruitflow®.

 

Fruitflow®

 

The syrup version of Fruitflow® continues to gain acceptance in the market. DSM has received a commitment by a significant dietary supplement marketer in Europe to launch Fruitflow in quarter two of 2012, this in addition to existing regional consumer healthcare customers in Europe, the US and Asia-Pacific markets. Fruitflow® travel shot concepts are being featured this week at the World Travel Catering & Onboard Services Expo in Hamburg.

 

Much focus is being given to the commercialisation of the powder version of the product. DSM is carrying out consumer research and in addition seeking further improvements in cost in use, in order to support ongoing discussions with global brand owners. The powder form will be widely available to dietary supplement manufacturers in the second half of 2012. This new form allows for broadening of sales into the traditional dietary supplement formats of tablets, capsules and soft gels.

 

Healthy interest in both formats of Fruitflow® continues to grow, with the highest interest being from dietary supplements brand owners. Fruitflow® is attracting attention from regional and global brand owners in all major global markets. To underpin this interest, strategic manufacturing facilities are in place for both formats, and registration of intellectual property in major markets has been completed.

 

Science in Sport

 

The business has performed strongly in March and the Company expects to finish the year with sales meeting the expectations of the Directors. Growth for the year has been strong across all key accounts in major multiple retailers including Tesco, and the wholesale channel which supplies the retail heartland of cycling, triathlon and running shops. While operating profit is, as expected, negatively affected by the off-season winter trading months and investment in the new factory, peak season trading is expected to be strong. Revenue growth is to be supported further by efficiencies from the new factory and a margin improvement programme, both of which will be used to fund marketing and sales investment.

 

The SiS brand will be relaunched during April and key elements include new branding and packaging, a new website with e-commerce capability, and two new product launches. In parallel, long-term sponsorship and ambassador arrangements have been signed with major Olympic and professional sports teams, as well as key opinion leaders from elite sport and nutritional science. These initiatives will underpin and develop the reputation of SiS as a highly regarded elite sports nutrition brand.

 

Other intellectual property

 

Unblinding of the Crohn's disease human trial data and subsequent analysis will be complete by the end of April and this will inform whether value can be extracted from the intellectual property through a sale to, or partnering arrangement with, a large healthcare business.

 

Financial position

 

£3.5m before expenses was raised during the summer of 2011 by way of a placing and open offer to fund the acquisition of SiS. The Company expects to report net cash of £1.3m at the year-end and this will be enhanced by the sale and lease back of the new factory plant. The Equity Financing Facility of £25m was renewed for a period of three years in November 2011. Restructuring of the business announced at the interim results has significantly reduced underlying cash usage and the effect of this was seen in the second half of the year. Expenditure continues to be monitored closely by the management team and Board.

 

Stephen Moon, CEO of Provexis, commented:

 

"This has been a year of great change and strong progress for the business. Our alliance with DSM continues to progress and we have strategic manufacturing in place, two commercially viable formats of Fruitflow®, and promising customer interest comprising brand owners in all major global markets from regional to global food, beverage and consumer healthcare companies.

 

The Science in Sport business is in strong sales growth and we have put a new supply chain platform in place, as well as bringing a new and substantially strengthened commercial team and viable growth strategy to bear. We intend to enhance our reputation as the leading elite sports nutrition brand.

 

The business has undergone a major transformation in order to focus on our two major commercial opportunities and we believe that the coming year will deliver good growth."

 

 

ends-

 

For further information please contact:

 

Provexis plc

Stephen Moon, Chief Executive Tel: 01753 861777

 

Cenkos Securities plc

Max Hartley / Bobbie Hilliam Tel: 020 7397 8900

 

Haggie Financial LLP

Matthew Longbottom / Peter Rigby Tel: 020 7417 8989

matthew.longbottom@haggie.co.uk

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTPGUMCWUPPGQB
Date   Source Headline
28th Mar 20247:00 amRNSIssue of Equity - purchase of Fruitflow® II SD
29th Dec 202312:48 pmRNSHalf-year Report
26th Oct 20231:51 pmRNSResult of AGM
29th Sep 20237:00 amRNSFinal Results
30th Aug 20237:04 amRNSBYHEALTH regulatory filing with Chinese SAMR
3rd Apr 20237:00 amRNSCapital structure and funding update
24th Jan 202311:03 amRNSGrant of Share Options
30th Dec 20228:53 amRNSHalf-year Report
27th Oct 20221:12 pmRNSResult of AGM
14th Oct 20227:00 amRNSDirectorate Change
30th Sep 20227:00 amRNSFinal Results
22nd Jun 20227:00 amRNSTwo new agreements with DSM & patent application
31st May 20225:00 pmRNSTotal Voting Rights
17th May 202212:39 pmRNSExercise of Options and Total Voting Rights
31st Dec 20217:00 amRNSHalf-year Report
26th Nov 20214:41 pmRNSSecond Price Monitoring Extn
26th Nov 20214:36 pmRNSPrice Monitoring Extension
4th Nov 20211:30 pmRNSResult of AGM
4th Nov 202111:07 amRNSBy-Health Fruitflow agreement and support in R&D
1st Oct 20216:04 pmRNSGrant of Share Options
30th Sep 20217:00 amRNSFinal Results
9th Sep 20214:41 pmRNSSecond Price Monitoring Extn
9th Sep 20214:35 pmRNSPrice Monitoring Extension
24th Aug 20214:35 pmRNSPrice Monitoring Extension
22nd Jul 20214:40 pmRNSSecond Price Monitoring Extn
22nd Jul 20214:35 pmRNSPrice Monitoring Extension
21st Jul 20214:41 pmRNSSecond Price Monitoring Extn
21st Jul 20214:36 pmRNSPrice Monitoring Extension
5th Jul 20214:35 pmRNSPrice Monitoring Extension
1st Jul 20214:40 pmRNSSecond Price Monitoring Extn
1st Jul 20214:35 pmRNSPrice Monitoring Extension
26th Feb 20215:00 pmRNSTotal Voting Rights
19th Feb 20217:30 amRNSDirector / PDMR notification
19th Feb 20217:00 amRNSPlacing of new ordinary shares to raise £50,000
29th Jan 202112:37 pmRNSHalf-year Report
31st Dec 20201:00 pmRNSTotal Voting Rights
17th Dec 20207:00 amRNS£1m placing & update re HY results
16th Nov 20207:00 amRNSExclusive Distribution Agreement for Chinese CBEC
30th Oct 20202:09 pmRNSResult of AGM
30th Sep 20207:00 amRNSFinal Results
28th Aug 20205:00 pmRNSTotal Voting Rights
13th Aug 20207:00 amRNSFruitflow® & Blood Pressure - purchase of IP
7th Aug 20205:11 pmRNSHolding(s) in Company
27th May 20207:00 amRNSHolding(s) in Company
31st Dec 20197:13 amRNSInterim Results and Total Voting Rights
11th Dec 20197:00 amRNSPlacing of new ordinary shares to raise £0.301m
4th Oct 20191:19 pmRNSResult of AGM
12th Sep 20193:19 pmRNSDirector/PDMR Shareholding
11th Sep 20194:02 pmRNSGrant of Share Options
10th Sep 20197:00 amRNSFinal Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.